Phoenix Venture Partners

Phoenix Venture Partners (PVP) is a venture capital firm that invests in and partners with entrepreneurs to commercialize breakthrough materials science innovations. PVP’s team has a track record of founding, building, and investing in successful materials science start-ups. The firm’s investment strategy is flexible and predicated on assisting entrepreneurs with customer and supply chain partnerships, business development, as well as strategic and operational support. PVP collaborates with a select set of forward-looking global corporations on business development and innovation interests. Phoenix Venture Partners was founded in 2010 and is based in Silicon Valley with satellite offices in Singapore and Cambridge, MA.

Chen, John T.

Founder and Managing General Partner

Christina Jenkins

Venture Partner

Zach Jonasson

Managing General Partner

Nobuyuki Kambe Ph.D

Co-Founder and Managing General Partner

Frank Levinson

Partner

Jennifer Wang

CFO

John Chen Ph.D

Co-Founder and Managing General Partner

Sheng Peng Ph.D

Venture Partner

36 past transactions

Biotia

Series A in 2022
Biotia is a health tech company spun out of Cornell Tech leveraging next-generation sequencing and artificial intelligence for rapid and precise infectious disease discovery. Their software and laboratory technology enable clinicians and researchers to guide patient treatment and improve health outcomes.

Autonomic Materials

Venture Round in 2022
Autonomic Materials is a manufacturer of corrosion-resistant chemicals to repair coating damage at the micron level. Its chemicals offer corrosion protection and respond to damage through coatings, adhesives, and composites that help customers to protect cars, bridges, ships, oil refineries, and other structures against corrosion and extend the lifetime and performance of the materials.

Eclipse Bioinnovations

Series A in 2022
Eclipse Bioinnovations is a leading RNA genomics company founded in 2017 based on technology developed at the University of California, San Diego. Eclipse's mission is to use their pioneering RNA genomics platform technologies to advance RNA medicines and scientific discovery. Eclipse’s founders developed eCLIP, the world’s most efficient and unique CLIP-seq technology for identifying RNA binding protein gene partners and gene maps. Eclipse’s suite of RNA genomics technologies now cover eCLIP-RBP for mapping the RNA binding proteins, miR-eCLIP for the miR-interactome, m6A-eCLIP for RNA modifications, End-Seq for 5' and 3' mapping, and FLI-Seq for simplifying Crispr library prep. Products are offered as services and kit for biopharma companies and academic researchers, and can be customized for clients.

InVivo AI

Seed Round in 2021
Valence Discovery is building the world’s most powerful chemistry engine. The company has pioneered the application of few-shot learning in drug design, along with the development of best-in-class AI methods for molecular representation, structure and ligand-based de novo design, and multiparameter optimization, enabling the design of novel chemistry against previously intractable biology.

Xandar Kardian

Series A in 2021
Xandar Kardian provides commercially deployed 99.9% 'true' presence detection and people (occupancy) count solutions for smart building applications. It's patented and proprietary occupancy count system is the world's first and only commercial grade system that is able to count from any open space (virtual zones), making foot traffic counting possible in areas that was not possible with traditional cameras. Using micro-vibration patterns emitted from the body (chest movement from breathing, heart beat frequency from the heart (BPM) movement inside the body), XK is able to obtain 95% repetitive accurate RHR and RR measurements continuously. Occupant wellness - either in an office space, factory, hospital, nursing home or residential homes is now possible continuously, autonomously and without using any cameras or wearable devices.

FibreCoat

Venture Round in 2021
FibreCoat GmbH produces thermoplastic-coated glass fibres for use in fibre composites on rented glass fibre drawing machines. Direct coating enables new process steps, lower costs and cycle times while at the same time improving technical specifications. The target markets are the automotive and consumer sectors.

Inkbit

Series B in 2021
Inkbit creats a next-generation additive manufacturing platform that combines 3D printing with machine vision. MIT-trained scientists and engineers combines expertise in industrial systems, design software, and material science to identify and seize opportunities for mass-market additive manufacturing.

FIGUR8

Series A in 2021
FIGUR8 is an MIT spin-off company, creating the most advanced wearable musculoskeletal (MSK) technology on the market. The solution combines Smart Biosensors, Intuitive Software and AI to analyze and advance musculoskeletal health. Our solution accurately pinpoints the source of MSK pathology and provides essential data to enhance patient-centric recovery. Value is recorded across the entire episode of care, from injury through full recovery. FIGUR8 technology aids in significantly reducing the cost of care, improving access, and empowering patients to take control of their personal MSK health.

Green Theme Technologies

Venture Round in 2021
Green Theme Technologies is a developer of environmentally-friendly, dry textile finishing technology. It is a textile innovation company with the mission to create products that out-perform existing technologies while eliminating water usage and pollution. The company was founded in 2012 and is based in Rio Rancho, New Mexico.

Cotsworks

Venture Round in 2021
Cotsworks manufactures rugged optical components for the commercial, military, aerospace, and industrial markets. The company was founded in 2006 and is based in Cleveland, Ohio, United States.

L7 Informatics

Series B in 2021
L7 Informatics, Inc. provides integrated scientific data and analytics solutions. The company offers a comprehensive platform that enables seamless data integration, advanced analytics, and collaborative workflows, empowering scientists and researchers to accelerate discoveries, improve operational efficiencies, and drive innovation. L7’s mission is to revolutionize how scientific data is managed, analyzed, and utilized, facilitating breakthroughs in research, drug discovery, development, and manufacturing. L7 Enterprise Science Platform (L7|ESP®) is a unified platform that contextualizes data and eliminates business silos via process orchestration. It is a comprehensive solution that facilitates the digitalization of data and scientific processes in life sciences organizations. It optimizes workflow orchestration and data management and improves task automation and execution.

Absci

Series E in 2020
Absci is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. We built our Integrated Drug Creation™ Platform to identify novel drug targets, discover optimal biotherapeutic candidates, and generate the cell lines to manufacture them in a single efficient process. Biotech and pharma innovators partner with us to create the next generation of protein-based drugs, including Bionic Proteins™ containing nonstandard amino acids, and other novel drug designs that may be impossible to make with other technologies. Our goal is to enable the development of better medicines by Translating Ideas into Drugs™. For more information visit www.absci.com.

WaveFront Dynamics

Series A in 2020
WaveFront Dynamics is a medical device company with innovative wavefront diagnostic technology for use in the vision care industry.

Micropore

Series C in 2020
Micropore manufactures reactive plastics which incorporate various powders into a molded matrix. The company's first product uses a CO2 adsorbent powder which is formed into a cartridge to create a revolutionary CO2 adsorbent system used in rebreathing and life support applications. The patented technology is the first major advance in CO2 adsorbent technology in over 100 years, providing superior performance advantages over existing granular adsorbents. It was founded in March of 1997 and is based in Elkton, Maryland.

Crop Enhancement

Series B in 2020
Crop Enhancement develop a new approach that will help farmers increase crop yields and profitability in a sustainable way. By developing agrochemical formulations that employ advanced and environmentally friendly chemistry, we help improve crop yields, eliminate or minimize pesticide use, and enable precise and effective delivery of active ingredients and fertilizers.

Absci

Series D in 2020
Absci is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. We built our Integrated Drug Creation™ Platform to identify novel drug targets, discover optimal biotherapeutic candidates, and generate the cell lines to manufacture them in a single efficient process. Biotech and pharma innovators partner with us to create the next generation of protein-based drugs, including Bionic Proteins™ containing nonstandard amino acids, and other novel drug designs that may be impossible to make with other technologies. Our goal is to enable the development of better medicines by Translating Ideas into Drugs™. For more information visit www.absci.com.
BroadSpot Imaging Corporation is developing a suite of diagnostic medical devices for eye care. They leverage advanced imaging technologies and small-scale, cloud-connected electronics to replace bulky, expensive diagnostic instruments with cost-effective handheld instruments and a series of valuable services. their technologies will fundamentally improve how eye care is delivered worldwide: eye doctors can see patients more efficiently, for less money, and more patients will gain access to high quality diagnostics as the population ages.

Absci

Series C in 2018
Absci is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. We built our Integrated Drug Creation™ Platform to identify novel drug targets, discover optimal biotherapeutic candidates, and generate the cell lines to manufacture them in a single efficient process. Biotech and pharma innovators partner with us to create the next generation of protein-based drugs, including Bionic Proteins™ containing nonstandard amino acids, and other novel drug designs that may be impossible to make with other technologies. Our goal is to enable the development of better medicines by Translating Ideas into Drugs™. For more information visit www.absci.com.

Comera Life Sciences

Series A in 2018
Comera Life Sciences is an engineering superior biotherapeutic formulation for fragile patients. Its proprietary technology provides patented, FDA-friendly excipients for a wide range of therapeutic biologics. Using its platforms, drug companies can make life-saving medicines easier to administer, less immunogenic, more stable, and more efficient to produce.

NBD Nanotechnologies

Series B in 2017
NBD develops coatings and additives to modify surface wetting properties. NBD focuses on coatings and additives that modify surface wettability. NBD's broad product portfolio can influence surface properties for glass and plastic materials to create ultra-durable and functional surface wetting properties. It was founded in 2012 and headquartered in Brighton, Massachusetts.

Furcifer Inc.

Series A in 2017
​Furcifer Inc. is a venture-backed Silicon Valley startup that focuses on developing and manufacturing of next-generation electrochromic films (smart films), with a broad range of applications that include automotive, real estate and electronic display markets.we
BroadSpot Imaging Corporation is developing a suite of diagnostic medical devices for eye care. They leverage advanced imaging technologies and small-scale, cloud-connected electronics to replace bulky, expensive diagnostic instruments with cost-effective handheld instruments and a series of valuable services. their technologies will fundamentally improve how eye care is delivered worldwide: eye doctors can see patients more efficiently, for less money, and more patients will gain access to high quality diagnostics as the population ages.

Absci

Series B in 2017
AbSci, LLC is a biotechnology company based in Portland, Oregon, specializing in protein production technologies for the biopharmaceutical industry. Founded in 2011, AbSci has developed SoluPro, an innovative expression system utilizing genetically engineered E. coli to facilitate the scalable and cost-effective production of antibodies, antibody fragments, and other soluble recombinant proteins. This technology significantly lowers production costs for both novel and existing biologics, enhancing the efficiency of drug discovery and manufacturing processes. AbSci's therapeutic proteins and antibodies play vital roles in treatments for cancer, hormone-related conditions, autoimmune diseases, and blood disorders. The company's approach integrates biologic drug discovery with cell line development, positioning it as a leader in the advancement of next-generation therapeutics.

C3Nano

Series D in 2017
C3Nano is the developer of the solution-based, transparent conductive inks and films as direct replacements for indium tin oxide (ITO). C3Nano is the performance leader in Transparent Conductor Films (TCFs) and Activegrid silver nanowire (AgNW) solution-based inks for the touch sensor and display industry. They have raised $37 million in funding to date, which has enabled the company to quickly achieve best in class ink formulations and expanded production capabilities. C3Nano is headquartered in Silicon Valley with an industry-leading manufacturing base in Korea. Founded in 2010, it is headquartered in Hayward, California.

Crop Enhancement

Series B in 2016
Crop Enhancement develop a new approach that will help farmers increase crop yields and profitability in a sustainable way. By developing agrochemical formulations that employ advanced and environmentally friendly chemistry, we help improve crop yields, eliminate or minimize pesticide use, and enable precise and effective delivery of active ingredients and fertilizers.

Nohms Technologies

Series B in 2016
NOHMs Technologies is developing materials and manufacturing processes for advanced lithium-ion battery electrolyte that enables twice the energy and runtime for half the cost in consumer electronics and electric vehicles via sales and licensing business model. The company's NanoLyte Electrolyte solutions contain new functional ionic liquid materials that significantly improve the performance and safety of next-generation lithium-ion batteries. NOHMs Technologies was founded in 2011 and is headquartered in Rochester, New York, United States.

Amber Molecular

Series A in 2016
Amber Molecular builds new light-emitting materials for organic light-emitting diodes in the display sector. Their materials have less perceived peak shifting due to their narrow emissions, eliminating the need for filters entirely.

Absci

Series A in 2016
Absci is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. We built our Integrated Drug Creation™ Platform to identify novel drug targets, discover optimal biotherapeutic candidates, and generate the cell lines to manufacture them in a single efficient process. Biotech and pharma innovators partner with us to create the next generation of protein-based drugs, including Bionic Proteins™ containing nonstandard amino acids, and other novel drug designs that may be impossible to make with other technologies. Our goal is to enable the development of better medicines by Translating Ideas into Drugs™. For more information visit www.absci.com.
Sentinel Monitoring Systems is at-line and in-line QC systems for ultra-rapid detection of microbial contamination. The Sentinel Online Monitor is a multivariate spectroscopic analyzer for real-time monitoring of bioburden and other target analytes. The Sentinel Sample Collector automatically collects excursion samples identified by online monitors and/or periodic samples during production runs. Other Sentinel products currently in development include automated online endotoxin monitoring and near real-time at-line systems for bioburden and specific organisms. It was founded in 2015 and is based in Tucson, Arizona.

C3Nano

Series C in 2014
C3Nano is the developer of the solution-based, transparent conductive inks and films as direct replacements for indium tin oxide (ITO). C3Nano is the performance leader in Transparent Conductor Films (TCFs) and Activegrid silver nanowire (AgNW) solution-based inks for the touch sensor and display industry. They have raised $37 million in funding to date, which has enabled the company to quickly achieve best in class ink formulations and expanded production capabilities. C3Nano is headquartered in Silicon Valley with an industry-leading manufacturing base in Korea. Founded in 2010, it is headquartered in Hayward, California.

NBD Nanotechnologies

Series A in 2014
NBD develops coatings and additives to modify surface wetting properties. NBD focuses on coatings and additives that modify surface wettability. NBD's broad product portfolio can influence surface properties for glass and plastic materials to create ultra-durable and functional surface wetting properties. It was founded in 2012 and headquartered in Brighton, Massachusetts.

Imprint Energy

Series A in 2014
Imprint Energy is commercializing a breakthrough low cost, flexible, rechargeable battery technology that will change portable power as the world knows it. Imprint aims to provide batteries with lithium-like performance at significantly lower costs and without form factor limitations or safety concerns. Imprint Energy will utilize its unique battery technology to address the energy needs of today's and tomorrow's electronic devices.

Autonomic Materials

Series B in 2012
Autonomic Materials is a manufacturer of corrosion-resistant chemicals to repair coating damage at the micron level. Its chemicals offer corrosion protection and respond to damage through coatings, adhesives, and composites that help customers to protect cars, bridges, ships, oil refineries, and other structures against corrosion and extend the lifetime and performance of the materials.

Vixar

Series B in 2012
Vixar is an early-stage start-up located in Plymouth, MN. Vixar manufactures high performance, cost-effective Vertical Cavity Surface Emitting Laser (VCSEL) products emitting at wavelengths ranging from 660 to 1850nm. VCSEL based components and subassemblies provide improved performance, size and energy efficiency for sensor and device applications within the biomedical, industrial, office product, military, automotive and consumer industries. Vixar was founded in 2005 by Dr. Klein Johnson and Dr. Mary Hibbs-Brenner. Drs. Johnson and Hibbs-Brenner were previously instrumental in establishing the VCSEL business at Honeywell serving the high speed fiber optic data communications market.

C3Nano

Series B in 2012
C3Nano is the developer of the solution-based, transparent conductive inks and films as direct replacements for indium tin oxide (ITO). C3Nano is the performance leader in Transparent Conductor Films (TCFs) and Activegrid silver nanowire (AgNW) solution-based inks for the touch sensor and display industry. They have raised $37 million in funding to date, which has enabled the company to quickly achieve best in class ink formulations and expanded production capabilities. C3Nano is headquartered in Silicon Valley with an industry-leading manufacturing base in Korea. Founded in 2010, it is headquartered in Hayward, California.

Senova Systems

Series B in 2012
Senova Systems develops, manufactures, and sells sensor systems by coupling its patented chemistry with advanced materials and proprietary microelectronics. Senova Systems’ first focus is a calibration-free pHit™ pH sensor platform that is wet-dry reversible and utilizes non-glass electrodes. This smart sensor platform marks the single most important technological advancement in the measurement of pH since the first pH meter in 1936 and will ultimately enable technological advances that were unachievable with conventional pH electrodes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.